Inclusion Criteria:
* Healthy male subjects aged 18 to 45 years (inclusive);
* Body weight ≥ 50.0 kg, with body mass index (BMI) between 19.0 and 26.0 kg/m² (inclusive);
* Subjects must be fully informed of the study and voluntarily sign the written informed consent form prior to the start of the study;
* Subjects who have no plan for fertility or sperm donation during the study period and within 1 year after completion of the study, and who agree to adopt strict contraceptive measures together with their sexual partners;
* Subjects with good hygiene habits, who are able to communicate well with the investigator and complete the study in accordance with the protocol requirements.
Exclusion Criteria:
* Subjects with clinically significant abnormal findings from vital sign measurements, physical examination, laboratory tests (complete blood count, blood biochemistry, urinalysis, coagulation function, thyroid function, fecal occult blood), 12-lead electrocardiogram (ECG), chest X-ray (posteroanterior view), or abdominal ultrasound (liver, gallbladder, pancreas, spleen, and kidneys) at screening, as judged by the investigator;
* Subjects with any positive result for hepatitis B surface antigen (HBsAg) or hepatitis B e antigen (HBeAg), hepatitis C virus antibody IgG (HCV-Ab IgG), HIV antigen/antibody (HIV Ag/Ab), or Treponema pallidum antibody;
* Subjects who have participated in any clinical trial and received an investigational drug or investigational medical device within 3 months prior to screening;
* Subjects who have used any drugs that inhibit or induce CYP or UGT enzymes within 4 weeks prior to screening;
* Subjects who have used any prescription drugs, over-the-counter drugs, vitamin products, health supplements, or herbal medicines within 14 days prior to screening;
* Subjects with habitual constipation or diarrhea;
* Subjects with hemorrhoids or perianal diseases accompanied by regular/ongoing hematochezia, irritable bowel syndrome, or inflammatory bowel disease;
* Subjects with atopic constitution, including a history of severe drug allergy or drug hypersensitivity, known allergy to the investigational product or to levofosfomycin, ornidazole, other nitroimidazole drugs or their excipients, or a history of food allergy;
* Subjects who have undergone major surgery within 6 months prior to screening or whose surgical incisions have not completely healed; major surgery includes but is not limited to any surgery with significant bleeding risk, prolonged general anesthesia, or open biopsy, or significant traumatic injury;
* Subjects with a history of any clinically significant disease or condition that may affect the study results, as judged by the investigator, including but not limited to diseases of the respiratory, cardiovascular, digestive, endocrine, neurological (e.g., epilepsy), urinary, hematological, immune, psychiatric, or metabolic systems;
* Subjects who are regular drinkers within 6 months prior to screening, i.e., consuming more than 14 units of alcohol per week (1 unit = 360 mL beer, or 45 mL of 40% spirit, or 150 mL wine); or those with alcoholism; or those with an alcohol breath test result \> 20 mg/dL at screening; or those who cannot abstain from alcohol during the study period;
* Subjects who smoke more than 5 cigarettes per day or habitually use nicotine-containing products within 3 months prior to screening, and who cannot abstain during the study period;
* Subjects who have used soft drugs (e.g., cannabis) within 3 months prior to screening or hard drugs (e.g., amphetamines, phencyclidine, etc.) within 1 year prior to screening; or those with a history of drug abuse; or those with a positive urine drug screening result at screening;
* Subjects who have consumed grapefruit, pomelo, dragon fruit, mango, or other fruits/products that affect metabolic enzymes within 7 days prior to screening;
* Subjects who habitually consume any foods or beverages rich in caffeine or xanthine (coffee, tea, cola, chocolate, etc.), or those who do not agree to abstain from such foods or beverages during the study period;
* Subjects with special dietary requirements who cannot comply with the unified diet;
* Subjects with a history of needle phobia or blood phobia, or those with difficulty in blood sampling or inability to tolerate venipuncture;
* Subjects engaged in occupations requiring long-term exposure to radioactive conditions; or those with significant radiation exposure within 1 year prior to the study (≥ 2 chest/abdominal CT scans, or ≥ 3 other types of X-ray examinations) or those who have participated in radiolabeled drug trials;
* Subjects who have donated blood with a total volume ≥ 400 mL or experienced total blood loss ≥ 400 mL within 3 months prior to screening, or donated blood with a total volume ≥ 200 mL or experienced total blood loss ≥ 200 mL or received blood transfusion within 1 month prior to screening, or those who plan to donate blood within 1 month after the end of this study;
* Subjects who are deemed by the investigator to have other factors that make them unsuitable for participation in this study.
